Recent

% | $
Quotes you view appear here for quick access.

NQ Mobile Inc. Message Board

holeinonein2002 13 posts  |  Last Activity: Feb 26, 2015 9:06 AM Member since: Aug 4, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • holeinonein2002 by holeinonein2002 Feb 26, 2015 9:06 AM Flag

    In light of the fact that the digital advertising niche has begun to see M&A activity, more deals are likely to follow suit. And Rocket Fuel looks to be the best buyout target in the group. That said, investors should never buy a stock solely on the basis of buyout hopes as many rumored deals fail to materialize. Yet even on its own merits, this stock holds great appeal. A buyout would merely be a kicker to the growth/value proposition. Simply moving up to an EV/sales ratio of 2.0, which would still be below the industry average, implies more than 100% upside for this beaten-down stock.

    Read more: http://www.nasdaq.com/article/how-i-used-ma-activity-to-find-an-undervalued-acquisition-target-cm395214#ixzz3SrMXoQGC

    Sentiment: Strong Buy

  • holeinonein2002 holeinonein2002 Feb 13, 2015 3:44 PM Flag

    New report dated 2/12/2015 ....Reni Benjamin Ph.D con't.....
    RNA world hypothesis—companies are flush with cash and may go shopping. A flurry of financing activity has given prominent companies, developing nucleic acid based therapeutics, cash to experiment with new partnerships, mergers, and acquisitions. Recent examples include Alnylam (ALNY; not rated) and Moderna therapeutics, which each raised $450 MM last month. Celsion has presented strong preclinical data showing that its TheraSilence platform can significantly knockdown several targets in including VEGFR-2 and the regulatory microRNA miR-145, with an approximate 50-fold preference for lung endothelium relative to other tissue types. The specificity for lung tissue and the one-component lipopolymer formulation distinguishes TheraSilence from other RNA delivery platforms, and we believe available preclinical data point to potential pulmonary applications for TheraSilence such as PAH, lung cancer, and cystic fibrosis. If correct, we believe the company has the potential to attract partnerships from one or more RNA companies currently evaluating Celsion’s uniquely-capable delivery platform.

    Sentiment: Strong Buy

  • Investment opinion. We are reiterating our Buy rating of Celsion and our 12-month target price of $8, based on a comparables analysis of similarly staged biotechnology companies. We recently had the opportunity to obtain an in-person update from the company’s management team, chiefly focusing on two assets that, in our opinion, inject new life into the company’s development programs and provide a crucial diversification for the company’s oncology-focused pipeline. While development of ThermoDox continues to advance in hepatocellular carcinoma (HCC) and recurrent chest wall breast cancer (RCWBC) and the company has identified a potential low-cost path to ThermoDox approval in China, we believe new assets centered on nucleic acid delivery, especially GEN-1 (formerly EGEN-001) and the TheraSilence platform, could generate significant shareholder value in the near-term. With both immuno-oncology and RNA-delivery assets taking center stage and approximately $35.7 MM in cash (pro forma) for clinical development, we believe Celsion represents an undervalued player with significant upside for the long-term.

    Sentiment: Strong Buy

  • Shorts didn't want to hear that....Good entry point her

    Sentiment: Strong Buy

  • holeinonein2002 by holeinonein2002 Feb 3, 2015 10:18 AM Flag

    Unlike producers and drillers CVEO can contract quickly and hunker down with reduced expenses...When the market improves they can ramp up quickly as well.

    Sentiment: Strong Buy

  • Hold on boys....CVEO is about to Rock and Roll...$6.00 is very realistic

    Sentiment: Strong Buy

  • holeinonein2002 by holeinonein2002 Jan 30, 2015 10:54 AM Flag

    Financial investors, including private equity firms and sovereign wealth funds, are expected to play a more active role in mergers and acquisitions in the oil and gas industry in the next few years, being attracted by buying opportunities resulting from declines in commodity prices since the summer, according to a new report from consulting firm A.T.
    The report concludes that financial investors are well-positioned to participate in merger and acquisition activities "given the stretched financials of some players."

    Sentiment: Strong Buy

  • The oil and gas business not that bad, coal in Australia sloppy.He went on to say they have many other opportunities such as Government as well as immigrant housing to diversify their business. This may be a hell of buy at 25% of Book Value.

    Sentiment: Strong Buy

  • ....Outlook, Changed To Stable From Positive

    Today's rating action was precipitated by the company's announcement that it plans to increase debt by at least $1 billion to fund accelerated international expansion in new territories and materially increase investment in original owned programming to support long-term growth and increase long-term profitability. The downgrade of the CFR to B1 is not a reflection of our view of the strategic benefits of completing the company's global footprint more quickly or increasing spending on owned original content. It reflects our view that the issuance of incremental debt to fund both the significantly increased negative cash flows for the new territory startup costs and the upfront working capital for the significant shift from licensing to production spending will lead to leverage levels meaningfully above the 4.0x sustained leverage upper threshold for the Ba3 rating during our two year rating horizon. We estimate that on a pro forma basis, an increase of $1 billion of total debt, will increase consolidated debt-to-EBITDA by about two turns to 4.3x from 2.3x (as of 12/31/2014 and incorporating Moody's standard adjustments). "Further, based on the company's public guidance for weaker operating results in 2015 relative to 2014, we believe that the combination of a decline in EBITDA over the near term and an increase in absolute debt levels will further push leverage past the limit appropriate for a Ba rating as that leverage could climb to over 6.0x in 2015," stated Neil Begley a Moody's Senior Vice president.

    Sentiment: Strong Sell

  • Knight Capital got 90+ offers after thei error

    Sentiment: Buy

  • holeinonein2002 by holeinonein2002 Jan 14, 2015 12:06 PM Flag

    Looks like the selling is drying up...Like the long side for a bounce

    Sentiment: Buy

  • holeinonein2002 by holeinonein2002 Jan 7, 2015 9:59 AM Flag

    While not as optimistic as smithts...he is absolutely right to buy when we have blood in the street...Jana saw value when the stock traded in the 20's, They took a tax loss at year end plain and simple
    My target is 12 in 12 months

    Sentiment: Strong Buy

  • "GEN-1 is designed to locally activate IL-12 production which can stimulate the patient's immune system to attack and destroy cancer," stated Dr. Nicolas Borys, Celsion's Senior Vice President and Chief Medical Officer.

    Sentiment: Strong Buy

NQ
3.83-0.03(-0.76%)Apr 1 4:08 PMEDT